These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. Bulcão C; Ribeiro-Filho FF; Sañudo A; Roberta Ferreira SG Am J Cardiovasc Drugs; 2007; 7(3):219-24. PubMed ID: 17610348 [TBL] [Abstract][Full Text] [Related]
49. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Lennernäs H; Fager G Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173 [TBL] [Abstract][Full Text] [Related]
50. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal. Pedersen TR; Tobert JA Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485 [TBL] [Abstract][Full Text] [Related]
51. Effect of simvastatin on trioleylglycerol hydrolysis and transacylation with cholesterol in serum of outpatients with coronary heart disease. Pioruńska-Stolzmann M; Pioruńska-Mikolajczak A; Mikolajczyk Z Drugs Exp Clin Res; 2003; 29(1):37-43. PubMed ID: 12866362 [TBL] [Abstract][Full Text] [Related]
52. Current and future treatment of hyperlipidemia: the role of statins. Farnier M; Davignon J Am J Cardiol; 1998 Aug; 82(4B):3J-10J. PubMed ID: 9737640 [TBL] [Abstract][Full Text] [Related]
53. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Rosenson RS Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000 [TBL] [Abstract][Full Text] [Related]
55. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. Hooiveld GJ; Vos TA; Scheffer GL; Van Goor H; Koning H; Bloks V; Loot AE; Meijer DK; Jansen PL; Kuipers F; Müller M Gastroenterology; 1999 Sep; 117(3):678-87. PubMed ID: 10464145 [TBL] [Abstract][Full Text] [Related]
56. Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Becker DJ; Gordon RY; Morris PB; Yorko J; Gordon YJ; Li M; Iqbal N Mayo Clin Proc; 2008 Jul; 83(7):758-64. PubMed ID: 18613992 [TBL] [Abstract][Full Text] [Related]
57. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Michelena HI; Osorio LA; Citkowitz E Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392 [TBL] [Abstract][Full Text] [Related]
58. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Nishimura T; Faul JL; Berry GJ; Vaszar LT; Qiu D; Pearl RG; Kao PN Am J Respir Crit Care Med; 2002 Nov; 166(10):1403-8. PubMed ID: 12406854 [TBL] [Abstract][Full Text] [Related]
59. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Wenke K; Meiser B; Thiery J; Nagel D; von Scheidt W; Steinbeck G; Seidel D; Reichart B Circulation; 1997 Sep; 96(5):1398-402. PubMed ID: 9315523 [TBL] [Abstract][Full Text] [Related]
60. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Laufs U; La Fata V; Plutzky J; Liao JK Circulation; 1998 Mar; 97(12):1129-35. PubMed ID: 9537338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]